Skip to Content

ARK Genomic Revolution ETF ARKG

Medalist Rating as of | See ARK Investment Hub

Morningstar’s Analysis ARKG

Will ARKG outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of a middling Process Pillar rating and a Below Average People Pillar rating limit ARK Genomic Revolution ETF to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 49.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

8.70 131.8 Mil
Healthcare

CRISPR Therapeutics AG

6.65 100.7 Mil
Healthcare

Recursion Pharmaceuticals Inc Class A

6.15 93.1 Mil
Healthcare

CareDx Inc

5.72 86.7 Mil
Healthcare

Intellia Therapeutics Inc

4.28 64.8 Mil
Healthcare

Schrodinger Inc Ordinary Shares

3.89 58.9 Mil
Healthcare

Ionis Pharmaceuticals Inc

3.62 54.9 Mil
Healthcare

Beam Therapeutics Inc

3.42 51.8 Mil
Healthcare

Arcturus Therapeutics Holdings Inc

3.38 51.1 Mil
Healthcare

Moderna Inc

3.33 50.4 Mil
Healthcare